natgillin/translations-raw huggingface dataset:
The method according to claim 10, wherein the antibody is selected from the group consisting of antibodies against ganglioside GD3, antibodies against human interleukin-5 receptor alpha-chain, antibodies against HER2, antibodies against CC chemokine receptor 4, antibodies against CD20, antibodies against CD22, antibodies against neuroblastoma, antibodies against MUC1, antibodies against epidermal growth factor receptor; in particular an antibody selected from the group consisting of Pankomab, Muromomab, Daclizumab, Basiliximab, Abciximab, Rituximab, Herceptin, Gemtuzumab, Alemtuzumab, Ibritumomab, Cetuximab, Bevacizumab, Tositumomab, Pavlizumab, Infliximab, Eculizumab, Epratuzumab, Omalizumab, Efalizumab, Adalimumab, OKT3, anti-CC chemokine receptor 4 antibody KM2160, and anti-neuroblastoma antibody chCE7. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što se protutijelo bira iz skupine koju čine protutijela protiv gangliozida GD3, protutijela protiv a-lanca receptora ljudskog interleukina-5, protutijela protiv HER2, protutijela protiv receptora 4 kemokina CC, protutijela protiv CD20, protutijela protiv CD22, protutijela protiv neuroblastoma, protutijela protiv MUCI, protutijela protiv receptora čimbenika rasta epiderme; osobito protutijelo koje se bira iz skupine koju čine Pankomab, Muromomab, Daklizumab, Baziliksimab, Abciksimab, Rituksimab, Herceptin, Gemtuzumab, Alemtuzumab, Ibritumomab, Cetuksimab, Bevacizumab, Tositumomab, Pavlizumab, Infliksimab, Ekulizumab, Epratuzumab, Omalizumab, Efalizumab, Adalimumab, OKT3, protutijelo KM2160 protiv receptora 4 kemokina CC i protutijelo chCE7 protiv neuroblastoma.
The resulting mixture is allowed to settle to give a green solution. 
Dobivenu smjesu se pusti stajati, čime se dobije zelenu otopinu.
The invention furthermore provides the use of a compound according to the above for the preparation of a pharmaceutical composition for the treatment of pain disorders, ADHD and stress urinary incontinence. 
Izum nadalje daje na raspolaganje korištenje spoja u skladu s gore navedenim za pripravak farmaceutskog sastava za liječenje boli, ADHDI urinarne inkontinencije uzrokovane stresom.
Use of an immobilized non-covalent complex of a neonatal Fc receptor (FcRn) and beta-2-microglobulin (b2m) as affinity chromatography ligand in an affinity chromatography with a positive linear pH gradient for separating antibodies or fusion polypeptides comprising at least an Fc-region, wherein the non-covalent complex of a neonatal Fc receptor and beta-2-microglobulin is bound to a chromatography material and the non-covalent complex is conjugated to the solid phase via a specific binding pair, wherein the pH gradient is from a first pH value to a second pH value whereby the first pH value is from pH 3.5 to pH 6.4 and the second pH value is from pH 7.4 to pH 9.5, and wherein the non-covalent complex of a neonatal Fc receptor (FcRn) and beta-2-microglobulin (b2m) is mono-biotinylated and the solid phase is derivatized with streptavidin. 
PATENTNI ZAHTJEVI Uporaba imobiliziranog nekovalentnog kompleksa neonatalnog Fc receptora (FcRn) i beta-2-mikroglobulina (b2m) kao liganda afinitetne kromatografije u jednoj afinitetnoj kromatografiji s pozitivnim linearnim pH gradijentom za razdvajanje protutijela ili fuzijskih polipeptida koji se sastoje barem od jednog Fc-područja, naznačena time, da je nekovalentni kompleks neonatalnog Fc receptora i beta-2-mikroglobulina vezan na kromatografski materijal, a nekovalentni kompleks je konjugiran na čvrstu fazu preko specifičnih veznih parova, pri čemu je pH gradijent od prve pH vrijednosti do druge pH vrijednosti, gdje je prva pH vrijednost od pH 3,5 do pH 6,4, a druga pH vrijednost je od pH 7,4 do pH 9,5, i pri čemu je nekovalentni kompleks neonatalnog Fc receptora (FcRn) i beta-2-mikroglobulina (b2m) mono-biotiniliziran, a čvrsta faza je derivirana iz streptavidina.
A method for identifying an individual with improved response to rostafuroxin, the method comprising detecting in an isolated DNA sample of the individual a single nucleotide polymorphism selected from the group consisting of rs234508, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375, in respectively, the nucleotide sequences of SEQ ID NO: 11, SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 5, SEQ ID NO: 3 and SEQ ID NO: 7, wherein the presence of the SNP (single nucleotide polymorphism) is correlated with an improved response to rostafuroxin in said individual said individual having at least one genotype selected from the group consisting of: genotype TT for rs2345088, heterozygous genotype C/T for rs16877182, genotype AA for rs16893522, genotype AA for rs246191 1, genotype TT for rs5013093, and genotype TT for rs12513375. 
Postupak za otkrivanje pojedinca s poboljšanim odgovorom na rostafuroksin, te postupak sadrži otkrivanje u izoliranom DNA uzorku pojedinca pojedinačnog nukleotidnog polimorfizma odabranog iz skupine koja sadrži 1s234508, rsl6877182, rsl6893522, rs2461911, rs5013093, i rsl2513375, u odgovarajućim, nukleotidnim sekvencama SEQ ID NO: I1, SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 5, SEQ ID NO: 3 i SEQ ID NO: 7, pri čemu prisutnost SNP (pojedinačnog nukleotidnog polimorfizma) korelira s poboljšanim odgovorom na rostafuroksin kod pojedinca te navedeni pojedinac ima barem jedan genotip odabran iz skupine koja sadrži: genotip TT za rs2345088, heterozigotni genotip C/T za rsl6877182, genotip AA za rs16893522, genotip AA za rs246191 1, genotip TT za rs5013093, te genotip TT za rs12513375.
The method as claimed in claim 57 wherein the licarbazepine acetate is mixed with 20-80 wt% of the total amount of binder. 
Postupak prema zahtjevu 13, naznačen time da se eslikarbazepin acetat miješa s 20-80 tež.% ukupne količine vezivnog sredstva.
The method of claim 1, wherein the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages. 
Antisens oligonukleotid u skladu sa zahtjevom 1, naznačen time što internukleotidne veze u oligonukleotidnoj okosnici su zamijenjene neprirodnim internukleotidnim vezama.
After filling lyophilization stoppers were placed and the vials were loaded in the lyophiliser at 5° C. Lyophilization process was performed according to the following table IX: TABLE IX Setpoint 
Nakon punjenja postavljeni su čepovi za liofilizaciju i ampule postavljene u liofilizator na 5?C. HR P20070374 T3 Proces liofilizacije je izveden prema sljedećoj tablici LX:
The apparatus of claim 8, wherein said supercritical fluid supply device further comprises a control valve for controlling pressure and flow rate of said supercritical fluid. The apparatus of claim 8, wherein said supercritical trough is further filled with distillation packing therein. 
Uređaj u skladu s patentnim zahtjevom 8, naznačen time što navedeni uređaj za dobavu superkritičnog fluida dodatno sadrži kontrolni ventil, radi kontroliranja tlaka i brzine protoka navedenog superkritičnog fluida.
eq. = equivalents In the following examples and procedures, the starting materials are available commercially from Aldrich Chemical Company, Inc., Milwaukee, Wis. 
U sljedećim primjerima i postupcima, početni materijali komercijalno su dostupni od Aldrich Chemical Company, Inc., Milwaukee, WI 53233 USA; Lancaster Synthesis, Inc., NH 03087 USA; Sigma, St.Louis MO 63178 USA; MAybridge Chemical Co.
The chewing gum composition according to any one of the preceding claims, wherein the chewing gum composition comprises an antioxidant. 
Pripravak u obliku žvakaće gume u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što pripravak u obliku žvakaće gume sadrži antioksidans.
A spray dispenser according to claim 1, wherein the spray dispenser is provided with a closure for inhibiting access to the container. 
Raspršivač sukladno bilo kojem prethodnom zahtjevu, pri čemu je raspršivač opremljen sredstvom (106) za zatvaranje radi sprječavanja pristupa u spremnik.
The composition according to claim 1, wherein the composition is a cough elixir or cough syrup. 
Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da pripravak je smjesa protiv kašlja ili sirup protiv kašlja.
amino acids having a sequence at least 80% identical to SEQ ID NO:363; 
aminokiseline koje imaju slijed najmanje 80% identičan slijedu SEQ ID NO:363; di.
the amino acid sequence selected from the group consisting of SEQ ID NOs 20 to 38 or 77 to 95; 
(a) amino kiselinsku sekvencu izabranu iz skupine koja se sastoji od SEQ ID Br. 20 do 38, 58 do 76 1 77 do 95;
The nano-fibrillar cellulose gel according to claim 15, characterized in that the Brookfield viscosity of the nano-fibrillar cellulose gel is lower than the Brookfield viscosity of a corresponding nano-fibrillar cellulose suspension having been fibrillated in the absence of fillers and/or pigments. 
HR P20171818 T1 naznačen time što viskoznost gela od nanofibrilarne celuloze prema Brookfieldu je manja od viskoznosti odgovarajuće suspenzije nanofibrilarne celuloze prema Brookfieldu jer je fibrilirana u odsutnosti punila i/ili pigmenata.
The electrochemical cell according to any of claims 9 to 14, wherein the separator comprises ceramic and/or glass particles, such as ceramic lithium aluminium titanium phosphate. 
Elektrokemijski članak u skladu s bilo kojim od patentnih zahtjeva 9 do 14, naznačen time što separator sadrži čestice karamike i/ili stakla, poput karamike od litijevog aluminijevog titanijevog fosfata.
30 % of ropinirole released by 2 hours; 
10 do 30 % ropinirola se oslobađa za 2 sata;
The isolated nucleic acid sequence of paragraph 1, wherein the CD3 zeta signaling domain is encoded by the nucleic acid sequence of SEQ ID NO: 18. 
(iv) signalni region 4-IBB je kodiran sekvencom SEQ ID NO: 17 i signalnu domenu CD3 zeta je kodiran sekvencom SEQ ID NO: 18;
The KLB modulator for use according to claims 1 or 5, wherein the KLB modulator is a KLB agonist. 
KL.f-agonist za uporabu prema zahtjevu 1 ili zahtjevu 2, naznačen time, da protutijelo anti-KLB je monoklonsko protutijelo.
A composition according to any preceding claim wherein the active principle is ciclosporin. 
Kompozicija prema zatjevu 16, naznačeno time da je aktivna tvar ciklosporin.
The protein for use in preventing or treating AIDS in a patient according to claims 1 to 3, wherein the protein is capable of stimulating an immune response against Tat proteins from two, three, four, five or more HIV-1 subtypes selected from A, B, C, D, E, F, G, H, J, and K. 
Protein za uporabu u prevenciji ili liječenju AIDS kod pacijenta prema zahtjevima 1 do 3, naznačen time da protein može stimulirati imuni odgovor protiv Tat proteina iz dva, tri, četiri, pet ili više podtipova HIV-1 koji su odabrani od A, B,C,D,E,F,G, H,J,iK.
Use of a protein-containing fermentation agent obtained by a process according to any one of claims 1 to 11, as a protein source in a feed material in an animal feed composition. 
Uporaba fermentacijskog sredstva koje sadrži proteine dobivene pomoću postupka prema bilo kojem od zahtjeva 1 do 11, naznačena time da je izvor proteina u krmivu za pripravak hrane za životinje.
The composition of embodiment 1, wherein the mRNA encodes an enzyme which is abnormally deficient in an individual with a lysosomal storage disorder. 
Sastav za upotrebu prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, gdje mRNA kodira enzim koji je neuobičajeno manjkav kod osobe s poremećajem lizozomske pohrane.
or from 40-90 % by weight andalusite, based on the total dry weight of the refractory composition, or andalusite and up to about 40 % by weight chamotte, based on the total dry weight of the refractory composition. 
naznačena time što vatrostalna mješavina koju se može torkretirati sadrži bilo od 50-95%, težinski, boksita, na osnovi ukupne suhe težine vatrostalne mješavine, ili od 40-90%, težinski, andaluzita, na osnovi ukupne suhe težine vatrostalne mješavine, ili andaluzita i do otprilike 40%, težinski, šamota, na osnovi ukupne suhe težine vatrostalne mješavine.
As indicated in Figure 4, a typical width of mist might be 5 to 15 centimeters wide at the harvested crop. 
Kako je prikazano na slici 4, tipična širina raspršene magle može biti 5 do 15 cm na ubranom usjevu.
More preferably, said device is adapted to produce a spray of composition having a mean droplet diameter greater than 20 microns, or even greater than 50 microns, or preferably greater than 75 microns. 
Uređaj za primjenu prema patentnom zahtjevu 10 ili 11 naznačen time što navedeni uređaj sadrži sprej pumpu, poželjno gdje je navedeni uređaj prilagođen da proizvodi sprej od kompozicije koji ima prosječni dijametar kapljice veći od 20 mikrona.
A pharmaceutical composition for oral or sublingual administration, comprising as active ingredient a salt of claim 1, together with one or more pharmaceutically acceptable carries, wherein the composition is in a solid or liquid form selected from a tablet, with or without coating, a capsule, a caplet, dragees, granules, a powder, a solution, and a syrup, wherein the composition contains from 0.5 to 5 g of the active ingredient in every tablet, capsule, dragee, granule or powder dose, or from 0.5–40% by weight of the active ingredient in a solution or syrup dose. 
Farmaceutski sastav, naznačen time, da on kao aktivan sastojak sadrži jednu od soli prema bilo kojem zahtjevu 1 do 4, koji sastav je predviđen za oralno ili suplingvalno davanje i da je on u obliku tableta, sa ili bez prevlake, kapsula, kapleta, dražeja, granula, praha ili otopina, koji sastav sadrži od 0,01 do 0,5 g aktivnog sastojka u svakoj tableti, kapsuli, dražeji, granuli ili dozi praha, ili je on u obliku 0,5-40%-tne masene otopine ili sirupa za oralno davanje.
seeding the solution; 
(f) zasijavanje otopine;
A substantially protein-free medium according to claims 1, 2, 3, or 4, wherein the amino acids are L-arginine, L-cystine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-alanine, L-taurine, L-glutamic acid, L-glutamine or glycine, or any combination thereof. 
Podloga značajno bez proteina prema patentnim zahtjevima 1, 2, 3 ili 4, naznačena time što su aminokiseline - L-arginin, L-cistin, L-histidin, L-izoleucin, L-leucin, L-lizin, L-metionin, L-fenilalanin, L-treonin, L-triptofan, L-tirozin, L-valin, L-alanin, L-taurin, L-glutaminska kiselina, L-glutamin ili glicin, ili bilo koja njihova kombinacija.
The method of claim 1, wherein the one or more polyols are selected from the group consisting of polyols containing two to seven carbon atoms and two to seven hydroxy groups, monosaccharides, disaccharides, polysaccharides, xantan gum, di-hydroxy acids and poly-hydroxy acids. 
Uporaba kako je zatraženo u zahtjevu 1 jednog ili više spojeva koji su odabrani iz skupine koja sadrži poliole koji sadrže dva do sedam ugljikovih atoma i dvije do sedam hidroksi skupina, monosaharide, disaharide, polisaharide kao što je škrob, celuloza, i njihovi derivati, dekstrin i maltodekstrin, ksantan guma, di-hidroksi kiseline i poli-hidroksi kiseline.
A fixed dose combination for use according to claim 7, wherein the fixed dose combination is administered twice daily. 
Kombinacija s fiksnom dozom u skladu s patentnim zahtjevom 10, naznačena time što se primjenjuje dva puta dnevno.
Preparation of Intermediates 
Priprema međuproizvoda
In some aspects, the antibody binds with high affinity to uncleaved HIV-1 gp160 trimers on a cell surface. 
Protutijelo u skladu s patentnim zahtjevom 6, naznačeno time što se protutijelo veže s visokim afinitetom na necijepane HIV-1 trimere gp160 na površini stanice.
The method of claim 6, wherein the mouse portion of the chimeric MHC II a polypeptide is encoded by a mouse H-2E a gene, and the human portion of the chimeric MHC II complex is encoded by a human HLA-DR4 a gene. 
Metoda 1z zahtjeva 11. gdje mišje MHC a odnosno (8 polipeptide kodiraju mišji geni H-2E a 1 f, a ljudski dio kimernog MHC II kompleksa kodiraju ljudski geni HLA-DR4 4.1 f.
Since a “normal” amount of PU was used, the flooring cleaning properties were very much improved compared to the reference without PU. 
Kako je korištena "uobičajena" količina PU-a, čišćenje podne obloge znatno je poboljšana u usporedbi s istima bez PU.
represents a C1-6 alkyl group substituted by one or two COOH and further optionally substituted by SO3H, or a salt thereof. 
predstavlja C1-6 alkilnu skupinu supstituiranu jednom ili dvjema skupinama COOH i dalje izborno supstituiranu skupinom SO3H, ili njezinu sol.
This example illustrates the effect of compounds of this as inhibitors of the glutathione S-transferase isoenzymes GST P1-1, A1-1, and M1-1, in vitro. 
Ovaj primjer ilustrira efekat spojeva kao inhibitora glutation S-transferaze izoenzima GST P1-1, Al-1 i MI-I, ix vitro.
The crude product was recrystallised form EtOH. 
Kruti produkt se rekristalizira iz EtOH.
(a5) an antigen-binding site comprising the H chain CDR 1, 2, and 3 having at least 70% sequence identity with amino acid sequences of zSEQ ID NOs: 87, 88, and 89, respectively; 
(a5) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 87, 88 odnosno 89 (H-lanac CDR-područja od Q153);
The engine (100) of claim 5, wherein the engine (100) is operable to initiate a combustion event in the expansion cylinder (104) while the expansion piston (114) is descending from its TDC position towards its BDC position. 
HR P20090436 T1 značajka je tog postupka da izgaranje plinova u ekspanzijskom cilindru (104) započinje nakon što ekspanzijski klip (114) dosegne svoju gornju mrtvu točku, tijekom ekspanzijskog takta, dok je prijelazni ventil (150) još uvijek otvoren.
The compound of Claim 10, or a pharmaceutically acceptable salt thereof, for use in the treatment of generalized anxiety disorder. 
Spoj u skladu s patentnim zahtjevom 10, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju generaliziranog anksioznog poremećaja.
Use of a polynucleotide encoding at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer. 
PATENTNI ZAHTJEVI Že Uporaba polinukleotida koji kodira polipeptid koji sadrži vanstanične IPT-3 i IPT-4 domene receptora faktora rasta hepatocita za pretraživanje farmakološki aktivnih tvari korisnih za liječenje raka.
The polypeptide of claim 1 wherein the first proximal end is within a long repeat of repeat portion VII. 
Polipeptid u skladu s patentnim zahtjevom 6, naznačen time što je prvi proksimalni kraj unutar ponavljanog dijela VII toksina A.
Thus, in a further embodiment of the above methods, the polymerization of the resin base is initiated by application of ultrasound. 
Stoga je daljnja cjelina gornjih metoda započinjanje polimerizacije baze za smolu primjenom ultrazvuka.
A compound, which is or a pharmaceutically acceptable salt or stereoisomer thereof. 
Spoj s formulom: ili njegova farmaceutski prihvatljiva sol ili stereoizomer.
The aryloazol-2-yl-cyanoethylamine compound of claims 1, 2 and 7 which is selected from 
Paraziticidni sastav prema zahtjevu 1, naznačen time, da je ariloazol-2-il-cijanoetilamino-spoj odabran od sljedećih:
In another preferred embodiment of the process of the invention the pH value of the solution obtained by a reaction of 2 mol of a basic amino acid with 1 mol of pentadecapeptide (SEQ ID NO: 1) is adjusted to 6.7 to 7.8, preferably to 7.40±0.05. 
Postupak prema zahtjevima 3 1 4, naznačen time, da se pHi-vrijednost otopine koja se dobiva putem reakcije od dva mola bazične aminokiseline s jednim molom pentadekapeptida sa (SEQ ID NO:I), prilagođava na 6,7 do 7,8, a poželjno do 7,40 € 0,05.
The antibody or antigen-binding fragment thereof as claimed in any one of claims 1-11, or the pharmaceutical composition as claimed in claim 12 for use in treatment of a disease or disorder associated with over-expression of hGM-CSF in a subject. 
Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 13, ili farmaceutski sastav prema zahtjevu 14, naznačen(o) time, da se upotrebljava za liječenje subjekta od bolesti ili poremećaja koji(a) je povezan(a) s prekomjernom ekspresijom hGM-CSF.
is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C1-4alkyl, C1-4alkyloxy, C1-4alkylsulfonyl, perfluoroC1-4alkyl, perfluoroC1-4alkyloxy, diC1-4alkylamino, hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C1-4alkyl and perfluoroC1-4alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C1-4alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C3-8 cycloalkyl; or C5-7cycloalkenyl; 
R je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, Cisalkil, Ciaalkiloksi, Ciaalkilsulfonil, perfluoroC,ualkil, perfluoroC,alkiloksi, diC,valkilamino, hidroksil, 1 fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, Ciaalkil 1 perfluoroC,aalkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo 1 C,aalkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; Cagcikloalkil; ili Csgcikloalkenil;
The mixture was added portion wise to a suspension of 4-nitrq benzoic acid chloride (150 mmol) in 1,2-dichloroethane (500 mL) and stirred at 60 °C over night. 
Smjesa se dodaje polako, u obrocima, u suspenziju klorid 4-benzojeve kiseline (150 mmol) u 1,2-dikloroetanu (500 ml) i miješa na 60 *C preko noći.
The coating of claim 10 produced from an aqueous slurry, wherein the aluminum powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between about 3.9 to 4.5 microns and the 90th percentile of the particle size distribution has a diameter of less than or equal to about 9.0 microns. 
Sastav obloge iz patentnog zahtjeva 7, pri čemu prah aluminija obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 3.9 i 4.5 mikrometara i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 9.0 mikrometara.
The method according to claim 2, wherein the interfacing layer (20) comprises one of non-woven fabric, net, a layer of sand. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što međusloj (20) sadrži komad netkane tkanine ili mrežu, ili
A construct comprising (i) the nucleotide sequence set forth in SEQ ID NO: 1 and (ii) a promoter that functions in plants, wherein the nucleotide sequence is operatively linked to the promoter such that the latter expresses a polypeptide sequence set forth in SEQ ID NO: 14. 
Konstrukt koji sadrži (i) nukleotidnu sekvencu prikazanu u SEQ ID NO: 1 i (ii) promotora koji djeluje u biljkama, naznačen time da je nukleotidna sekvenca funkcionalno povezana na promotor tako da ovaj eksprimira polipeptidnu sekvencu prikazanu u SEQ ID NO: 14.
According to a preferred embodiment, Z1 is selected from the group consisting of 1-(diphenylmethyl)piperazine; 
Sol prema zahtjevu 2 ili 3, naznačena time, da Z' je odabran iz skupine koju čine:
A synergistic herbicidal mixture as claimed in claim 1 in which the sulfonyl urea is selected from the group consisting of nicosulfuron, tritosulfuron, mesosulfuron, cyclosulfamuron, rimsulfuron, foramsulfuron including their respective isomers as well as their respective environmentally compatible salts or esters or amides or other derivatives. 
Sinergistička herbicidna smjesa prema patentnom zahtjevu 1, naznačena time što su kloroacetamidi, uključujući njihove odgovarajuće izomere kao i njihove odgovarajuće sa životnom sredinom kompatibilne soli, estere, amide 1li druge derivate, izabrani iz grupe koju čine metazaklor, metolaklor i dimetenamid.